🔐

Sequencemedicine

enter passkey to continue

incorrect passkey

SequenceMedicine

Evidence-based genetic testing indications for clinical genetics

A curated compendium of exome and genome sequencing indications across 22 organ systems, grounded in published diagnostic yields and supported by 189 literature references. Built for clinicians ordering and interpreting genomic tests.

Diagnostic Yield by Organ System

Percentage of patients receiving a molecular diagnosis through genetic testing. Strong-evidence systems with published yield data from peer-reviewed literature.

The Diagnostic Odyssey vs. CarePathway

Today's rare disease patients cycle through years of specialists, imaging, and empiric treatments. A CarePathway collapses this into a single diagnostic episode.

    graph LR
      subgraph odyssey["Traditional Diagnostic Odyssey — 5-7 Years"]
        direction LR
        A1["Patient\nSymptoms Onset"] --> A2["PCP Visit\n$200"]
        A2 --> A3["Specialist #1\n$500"]
        A3 --> A4["Imaging\n$2,500"]
        A4 --> A5["Specialist #2\n$500"]
        A5 --> A6["Lab Work\n$1,200"]
        A6 --> A7["Specialist #3\n$500"]
        A7 --> A8["Exploratory\nProcedure\n$15,000"]
        A8 --> A9["Specialist #4\n$500"]
        A9 --> A10["Maybe\nDiagnosis?"]
      end
      subgraph pathway["CarePathway — Weeks"]
        direction LR
        B1["Patient\nScreening\nRed Flags"] --> B2["Genetic\nCounseling\n$200"]
        B2 --> B3["Genetic Test\n$250–3,000"]
        B3 --> B4["Molecular\nDiagnosis"]
        B4 --> B5["Targeted\nTherapy"]
      end
      style odyssey fill:#fef2f2,stroke:#fca5a5
      style pathway fill:#dcfce7,stroke:#86efac
      style A10 fill:#fecaca,stroke:#ef4444,color:#991b1b
      style B4 fill:#bbf7d0,stroke:#16a34a,color:#14532d
      style B5 fill:#bbf7d0,stroke:#16a34a,color:#14532d
    

Cost Impact: Testing vs. Avoided Spend

A single genetic test costing $250–$3,000 can prevent $50,000–$500,000+ in unnecessary downstream care.

Organ System Genetic Test Cost Avg. Pre-Dx Spend Potential Savings Yield
Musculoskeletal $250 – $3,000 $80,000 – $250,000 $77,000 – $247,000 50–89%
Neurological $250 – $3,000 $100,000 – $500,000 $97,000 – $497,000 43–58%
Cardiovascular $250 – $1,500 $50,000 – $200,000 $48,500 – $198,500 32–67%
Nephrology $250 – $3,000 $75,000 – $300,000 $72,000 – $297,000 46–81%
Indications Compendium
Organ-system-organized indications for exome and genome sequencing with diagnostic yield ranges and evidence tiers.
22 Organ Systems
Living Literature Review
Curated evidence references supporting diagnostic yield data and clinical utility of genomic testing.
189 References
Clinical Impact & Efficacy
Outcomes data and clinical utility metrics demonstrating the real-world impact of genomic testing.
Coming Soon
Clinical Case Presentations
De-identified case studies illustrating how genomic testing changed diagnosis and management.
Coming Soon
$1T
Annual U.S. Rare Disease Cost
30M
Americans Affected
5–7 yrs
Avg. Diagnostic Odyssey
89%
Highest Diagnostic Yield

Genetic testing collapses years of diagnostic workup into a single definitive answer — turning unresolved high-cost utilization into case closure.

Explore by Organ System

Diagnostic yields and ES/GS indications organized by clinical system. Sorted by evidence strength.

Strong evidence
Moderate evidence
Emerging evidence
Auditory/Hearing
Strong
39-67%
3 ES/GS indications
Cardiovascular
Strong
32-67%
4 ES/GS indications
Connective Tissue
Strong
17-18%
5 ES/GS indications
Craniofacial
Strong
15-84%
5 ES/GS indications
Developmental
Strong
27-41%
5 ES/GS indications
Endocrine
Strong
28-59%
3 ES/GS indications
Gastrointestinal
Strong
25-64%
6 ES/GS indications
Hepatic/Liver
Strong
25-60%
4 ES/GS indications
Immunologic
Strong
15-79%
4 ES/GS indications
Hematologic/Lymphatic
Strong
15-79%
6 ES/GS indications
Metabolic/Biochemical
Strong
88-90%
5 ES/GS indications
Musculoskeletal
Strong
50-89%
4 ES/GS indications
Nephrology/Renal
Strong
46-81%
5 ES/GS indications
Neurological
Strong
43-58%
5 ES/GS indications
NICU — Rapid Genomic Sequencing
Strong
34-59%
11 ES/GS indications
Ophthalmic
Strong
49-92%
5 ES/GS indications
PICU/CICU — Rapid Genomic Sequencing
Strong
31-59%
10 ES/GS indications
Pulmonary
Strong
47-80%
3 ES/GS indications
Skeletal
Strong
42-69%
4 ES/GS indications
Dermatologic
Strong
58-95%
3 ES/GS indications
Psychiatric/Behavioral
Moderate
9-57%
2 ES/GS indications
Reproductive
Moderate
1.5-60%
5 ES/GS indications

CarePathways

Structured, evidence-based clinical care pathways that bundle genetic testing into value-based delivery models — organized by specialty.

SequenceONC
Oncology Pathways
SequenceEDS
Ehlers-Danlos Syndromes
SequenceNGx
Neurogenomics
SequenceNDD
Neurodevelopmental Disorders
SequenceCKD
Chronic Kidney Disease
SequenceCVD
Cardiovascular Disease